Javascript must be enabled to continue!
The Peripubertal Gender-Dysphoric Child: Puberty Suppression and Treatment Paradigms
View through CrossRef
Gender-nonconforming youth are emerging at increasingly younger ages, and those experiencing gender dysphoria are seeking medical care at, or sometimes even before, the onset of puberty. Youth with gender dysphoria are at high risk for depression, anxiety, isolation, self-harm, and suicidality at the onset of a puberty that feels wrong. Medical providers would benefit from understanding interventions that help gender-nonconforming children and youth thrive. The use of gonadotropin-releasing hormone (GnRH) agonists to block the onset of an undesired puberty in youth with gender dysphoria is a relatively new practice, particularly in the United States. These medications shut down the hypothalamic-pituitary-gonadal axis (HPG), and the production of either testosterone or estrogen is temporarily halted. Puberty blocking allows a young person to explore gender and participate more fully in the mental health therapy process without being consumed by the fear of an impending developmental process that will result in the acquisition of undesired secondary sexual characteristics. GnRH agonists have been used safely for decades in children with other medical conditions, including central precocious puberty. Potential side effects of GnRH agonists include diminished bone density, injection site problems, emotional instability, and weight gain. Preliminary data have shown GnRH agonists to be very helpful in improving behavioral and overall functioning outcomes. Puberty suppression should ideally begin in the first stages of pubertal development and can be given via intramuscular or subcutaneous injections, or via an implant that is inserted in the upper arm. Monitoring to assure suppression of the HPG axis should occur regularly. Gender-nonconforming youth who remain gender dysphoric can go on to receive cross-sex hormones for phenotypic gender transition when they are older. GnRH agonists have changed the landscape of medical intervention for youth with gender dysphoria and are rapidly becoming the standard of practice.
[
Pediatr Ann
. 2014; 43(6):e132–e137.]
Title: The Peripubertal Gender-Dysphoric Child: Puberty Suppression and Treatment Paradigms
Description:
Gender-nonconforming youth are emerging at increasingly younger ages, and those experiencing gender dysphoria are seeking medical care at, or sometimes even before, the onset of puberty.
Youth with gender dysphoria are at high risk for depression, anxiety, isolation, self-harm, and suicidality at the onset of a puberty that feels wrong.
Medical providers would benefit from understanding interventions that help gender-nonconforming children and youth thrive.
The use of gonadotropin-releasing hormone (GnRH) agonists to block the onset of an undesired puberty in youth with gender dysphoria is a relatively new practice, particularly in the United States.
These medications shut down the hypothalamic-pituitary-gonadal axis (HPG), and the production of either testosterone or estrogen is temporarily halted.
Puberty blocking allows a young person to explore gender and participate more fully in the mental health therapy process without being consumed by the fear of an impending developmental process that will result in the acquisition of undesired secondary sexual characteristics.
GnRH agonists have been used safely for decades in children with other medical conditions, including central precocious puberty.
Potential side effects of GnRH agonists include diminished bone density, injection site problems, emotional instability, and weight gain.
Preliminary data have shown GnRH agonists to be very helpful in improving behavioral and overall functioning outcomes.
Puberty suppression should ideally begin in the first stages of pubertal development and can be given via intramuscular or subcutaneous injections, or via an implant that is inserted in the upper arm.
Monitoring to assure suppression of the HPG axis should occur regularly.
Gender-nonconforming youth who remain gender dysphoric can go on to receive cross-sex hormones for phenotypic gender transition when they are older.
GnRH agonists have changed the landscape of medical intervention for youth with gender dysphoria and are rapidly becoming the standard of practice.
[
Pediatr Ann
.
2014; 43(6):e132–e137.
].
Related Results
Hypogonadism in Thalassemia Major.
Hypogonadism in Thalassemia Major.
Abstract
Thalassemia is one of the commonest hereditary hemolytic anemia. 3% to 17% of the population in Indian subcontinent carries beta thalassemia gene. Every yea...
Evaluation of etiology and clinical feature of precocious puberty among children presenting in a pediatric endocrinology department in a tertiary care hospital.
Evaluation of etiology and clinical feature of precocious puberty among children presenting in a pediatric endocrinology department in a tertiary care hospital.
Objective: To find the frequency of precocious puberty in children and to compare the clinical and laboratory parameters of central & peripheral precocious puberty. Study Desig...
Advancing Puberty in the Black Carp (Mylopharyngodon piceus) and the Striped Bass (Morone saxatilis)
Advancing Puberty in the Black Carp (Mylopharyngodon piceus) and the Striped Bass (Morone saxatilis)
Both the genes and cDNA sequences encoding the b-subunits of black carp LH and FSH were isolated, cloned and sequenced. Sequence analysis of the bcFSHb and LHb5'flanking regions re...
Do parent posttraumatic stress symptoms (PTSS) predict later child PTSS?
Do parent posttraumatic stress symptoms (PTSS) predict later child PTSS?
Background: Although research suggests that parent and child PTSS are associated, the magnitude of this association at different time points and in the context of various covariate...
The Impact of Father Involvement in the Early Childhood Problematic Behavior
The Impact of Father Involvement in the Early Childhood Problematic Behavior
Father's involvement is something that influences the child's problematic behavior. The purpose of this study is to investigate whether father involvement can influence children's ...
Time of puberty in females and cognitive performance
Time of puberty in females and cognitive performance
Biological processes associated with puberty have been researched extensively. However, the relationship between time of puberty in females and cognitive performance remains unclea...
Precocious puberty: diagnosis and management
Precocious puberty: diagnosis and management
Precocious puberty is commonly defined as puberty that starts before age 8 years in girls and 9 years in boys. The causes of it may range from a variant of normal development to va...
Clinical Management and Therapy of Precocious Puberty in the Sapienza University Pediatrics Hospital of Rome, Italy
Clinical Management and Therapy of Precocious Puberty in the Sapienza University Pediatrics Hospital of Rome, Italy
Puberty identifies the transition from childhood to adulthood. Precocious puberty is the onset of signs of pubertal development before age eight in girls and before age nine in boy...

